Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis

Experimental Parasitology

Volumn 129, Issue 2, 2011, Pages 107-114

  Tafaghodi, Mohsen ^a   Eskandari, Maryam ^a   Khamesipour, Ali ^b   Jaafari, Mahmoud R ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alginate microsphere; Autoclaved Leishmania major (ALM); CpG ODN; Leishmaniasis; Vaccine

Indexed keywords

ALGINATE MICROSPHERE; ALGINIC ACID; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; LEISHMANIA MAJOR VACCINE; LEISHMANIA VACCINE; MICROSPHERE; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AUTOCLAVE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMULSION; ENCAPSULATION; FEMALE; IMMUNE RESPONSE; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPLEEN CELL; SWELLING;

ADJUVANTS, IMMUNOLOGIC; ALGINATES; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EMULSIONS; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; MOLECULAR WEIGHT; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN;

LEISHMANIA MAJOR; MURINAE; MUS;

EID: 80052412990     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.07.007     Document Type: Article

References (54)

1. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. European Journal of Immunology 2002, 32:1958-1968.
2. Alimohammadian M.H., Khamesipour A., Darabi H., Firooz A., Malekzadeh S., Bahonar A., Dowlati Y., Modabber F. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 2002, 21:174-180.
3. Armijos R.X., Weigel M.M., Calvopina M., Hidalgo A., Cevallos W., Correa J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004, 22:1320-1326.
4. Badiee A., Jaafari M.R., Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Experimental Parasitology 2007, 115:127-134.
5. Bahar K., Dowlati Y., Shidani B., Alimohammadian M.H., Khamesipour A., Ehsasi S., Hashemi-Fesharki R., Ale-Agha S., Modabber F. Comparative safety and immunogenicity trial of two killed leishmania major vaccines with or without bcg in human volunteers. Clinics in Dermatology 1996, 14:489-495.
6. Barman S.P., Lunsford L., Chambers P., Hedley M.L. Two methods for quantifying DNA extracted from poly(lactide-co-glycolide) microspheres. Journal of Controlled Release 2000, 69:337-344.
7. Bhowmick S., Ravindran R., Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 2007, 25:6544-6556.
8. Cabrera M., Blackwell J.M., Castes M., Trujillo D., Convit J., Shaw M.A. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunology 2000, 22:73-79.
9. Coelho E.A., Tavares C.A., Lima Kde M., Silva C.L., Rodrigues J.M., Fernandes A.P. Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania major infection. Parasitology Research 2006, 98:568-575.
10. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., Toledo V.P., Costa C.A., Genaro O., Mendonca S.C.F. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 1999, 17:1179-1185.
11. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. Journal Of Controlled Release 2002, 85:247-262.
12. Flynn B., Wang V., Sacks D.L., Seder R.A., Verthelyi D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infection and Immunity 2005, 73:4948-4954.
13. Follador I., Araujo C., Orge G., Cheng L.H., de Carvalho L.P., Bacellar O., Almeida R.P., Carvalho E.M. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 2002, 20:1365-1368.
14. Fundueanu G., Esposito E., Mihai D., Carpov A., Desbrieres J., Rinaudo M., Nastruzzi C. Preparation and characterization of Ca-alginate microspheres by a new emulsification method. International Journal of Pharmaceutics 1998, 170:11-21.
15. Gupta R.K., Siber G.R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995, 13:1263-1276.
16. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
17. Iborra S., Carrion J., Anderson C., Alonso C., Sacks D., Soto M. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infection and Immunity 2005, 73:5842-5852.
18. Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., Barkhordari F., McMaster W.R., Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25:6107-6117.
19. Jaafari M.R., Ghafarian A., Farrokh-Gisour A., Samiei A., Kheiri M.T., Mahboudi F., Barkhordari F., Khamesipour A., McMaster W.R. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 2006, 24:5708-5717.
20. Javadian E., Nadim A., Tahvildare-Bidruni G., Assefi V. Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan Part V: Report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 1976, 69:140-143.
21. Kamil A.A., Khalil E.A., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., Zijlstra E.E., Sacks D., Smith P.G., Zicker F., El-Hassan A.M. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003, 97:365-368.
22. Kedzierski, L., Zhu, Y., and Handman, E., 2006. Leishmania vaccines: progress and problems. Parasitology 133 Suppl, S87-112.
23. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., Ibrahim M.E., Kamil A.A., Elsheikh M., Babiker, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356:1565-1569.
24. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., Modabber F. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
25. Khamesipour A., Rafati S., Davoudi N., Maboudi F., Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian Journal of Medical Research 2006, 123:423-438.
26. Krieg A.M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1999, 1489:107-116.
27. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 2002, 20:709-760.
28. Lemoine D., Wauters F., Bouchend'homme S., Preat V. Preparation and characterization of alginate microspheres containing a model antigen. International Journal of Pharmaceutics 1998, 176:9-19.
29. Mauel J. Vaccination against Leishmania infections. Current Drug Targets and Immune Endocrine, Metabolic Disorders 2002, 2:201-226.
30. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. Journal of Immunology 1998, 161:4463-4466.
31. Mendez S., Tabbara K., Belkaid Y., Bertholet S., Verthelyi D., Klinman D., Seder R.A., Sacks D.L. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infection and Immunity 2003, 71:5121-5129.
32. Misra A., Dube A., Srivastava B., Sharma P., Srivastava J.K., Katiyar J.C., Naik S. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001, 19:3485-3492.
33. Mittal S.K., Aggarwal N., Sailaja G., van Olphen A., HogenEsch H., North A., Hays J., Moffatt S. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000, 19:253-263.
34. Modabber F. Vaccines against leishmaniasis. Annals of Tropical Medicine and Parasitology 1995, 89:83-88.
35. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district. I.R. Iran. Vaccine 2004, 22:4097-4100.
36. Noazin S., Khamesipour A., Moulton L.H., Tanner M., Nasseri K., Modabber F., Sharifi I., Khalil E.A., Bernal I.D., Antunes C.M., Smith P.G. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 2009, 27:4747-4753.
37. Noazin S., Modabber F., Khamesipour A., Smith P.G., Moulton L.H., Nasseri K., Sharifi I., Khalil E.A., Bernal I.D., Antunes C.M., Kieny M.P., Tanner M. First generation leishmaniasis vaccines: A review of field efficacy trials. Vaccine 2008, 26:6759-6767.
38. Rebelatto M.C., Guimond P., Bowersock T.L., HogenEsch H. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Veterinary Immunology and Immunopathology 2001, 83:93-105.
39. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annual Review of Immunology 1995, 13:151-177.
40. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., Turon T.N., Davey D.F., Davis H., Klinman D.M., Coler R.N., Sacks D.L., Seder R.A. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. Journal of Experimental Medicine 2002, 195:1565-1573.
41. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nature Reviews. Immunology 2002, 2:845-858.
42. Satti I.N., Osman H.Y., Daifalla N.S., Younis S.A., Khalil E.A., Zijlstra E.E., El Hassan A.M., Ghalib H.W. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001, 19:2100-2106.
43. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model I. Induction of protective immunity with a soluble extract of promastigotes. Journal of Immunology 1987, 139:221-227.
44. Shimizu Y., Takagi H., Nakayama T., Yamakami K., Tadakuma T., Yokoyama N., Kojima N. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunology 2007, 29:229-239.
45. Shimizu Y., Yamakami K., Gomi T., Nakata M., Asanuma H., Tadakuma T., Kojima N. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorganic and Medicinal Chemistry 2003, 11:1191-1195.
46. Sinha V.R., Trehan A. Biodegradable microspheres for protein delivery. Journal of Controlled Release 2003, 90:261-280.
47. Tafaghodi M., Jaafari M.R., Sajadi Tabassi S.A. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. European Journal of Pharmaceutics and Biopharmaceutics 2006, 64:138-145.
48. Tafaghodi, M., Khamesipour, A., and Jaafari, M.R., Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitology Research (doi:). doi:10.1007/s00436-010-2176-4.
49. Tafaghodi M., Sajadi Tabassi S.A., Jaafari M.R. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. International Journal of Pharmaceutics 2006, 319:37-43.
50. Tewary P., Pandya J., Mehta J., Sukumaran B., Madhubala R. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. FEMS Immunology and Medical Microbiology 2004, 42:241-248.
51. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. Journal of Immunology 2002, 168:1659-1663.
52. Waterborg J.H. Quantitation of proteins. The Protein Protocols Handbook 2002, 3-36. Humana Press, New Jersey. J. Walker (Ed.).
53. World Health Organization, 2004. Disease watch. focus: Leishmaniasis. http://www.who.int/tdr/dw/leish2004.htm.
54. Wu W., Weigand L., Belkaid Y., Mendez S. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. European Journal of Immunology 2006, 36:3238-3247.